Table 4.
| Summary of VC-related Clinical Trials
| Author(s) and year study start to completion (or expectation) | Number of cases | Clinical trial status | Research content | Clinical trial number |
|---|---|---|---|---|
|
Ercan Ok 2006–2008 |
446 | Completed | Effects of atorvastatin therapy on coronary artery calcification progression, carotid intima-media thickness progression, endothelial function, and inflammation in hemodialysis patients | NCT00481364 |
|
Amgen 2006–2009 |
360 | Completed | Whether cinacalcet plus low-dose vit D attenuated the progression of VC over one year compared with the use of flexible vit D doses in patients with chronic kidney disease receiving hemodialysis | NCT00379899 |
|
Peter G Kerr 2007–2009 |
50 | Completed | Effects of alendronate sodium on cardiovascular and bone mineral parameters | NCT00395382 |
|
Sinee Disthabanchong 2008–2009 |
50 | Completed | The treatment effect of sodium thiosulfate on coronary calcification in patients on hemodialysis | NCT00720772 |
|
Karen E Yeates 2008–2013 |
25 | Completed | Effect of bisphosphonates on VC in adult dialysis patients | NCT00687661 |
|
Sylvia E Rosas 2008–2013 |
44 | Completed | Different forms of vit D may have differential effects in VC progression in CKD patients | NCT00752102 |
|
Angela YM Wang 2010–2017 |
67 | Completed | Effects of oral cinacalcet and parathyroidectomy combined with forearm autografting on coronary artery and valve calcification progression and left ventricular mass index in end-stage renal disease patients receiving peritoneal dialysis for more than 12 months | NCT01447368 |
|
Shih-Li Su 2011–2012 |
60 | Completed | Effect of vit K2 on human osteoporosis, VC and sclerosis | NCT01928134 |
|
Rogier Caluwé 2011–2012 |
165 | Completed | Find the best dose of vit K2 for hemodialysis patients | NCT01675206 |
|
Rachel Holden 2012–2019 |
85 | Completed | Whether vit K supplements three times a week reduce the progression of coronary artery calcification in dialysis patients over a 12-month period | NCT01528800 |
|
Alessandra Brofferio 2012–2021 |
7 | Completed | Whether etidronate sodium is safe and effective in treating Arterial Calcifications due to Deficiency in CD73 (ACDC) | NCT01585402 |
|
Jürgen Floege 2013–2020 |
63 | Completed | Taking vit K1 to slow progression of VC in HD patients | NCT01742273 |
|
Ana Paula S Gueiros 2014–2016 |
33 | Completed | The effect of spironolactone in the progression of coronary calcification in patients undergoing peritoneal dialysis | NCT03314493 |
|
Iain O Bressendorff 2015–2021 |
148 | Completed | Effect of oral magnesium supplements on VC in patients with CKD | NCT02542319 |
| Rogier Caluwe 2015–2019 | 117 | Completed | Whether the replacement of vit K antagonists with Rivaroxaban slows VC and whether the addition of vit K2 to Rivaroxaban further slows the progression of VC | NCT02610933 |
|
Mabel Aoun 2016–2016 |
50 | Completed | Assess the rate of decrease of dp-ucMGP in a hemodialysis cohort after supplementation with vit K2 and the correlation between this rate of decrease and the Aortic Calcification Severity (AC24) score | NCT02876354 |
|
Rocío Pérez Abud 2016–2017 |
59 | Completed | The effect of vit K2 on VC in patients on hemodialysis | NCT04539418 |
|
Alex Gold 2016–2019 |
274 | Completed | Effect of 2 dose levels of SNF472 on progression of coronary calcium volume scores in patients with HDESRD over a 12-month period compared with placebo | NCT02966028 |
|
Krishna Singh 2016–2020 |
102 | Completed | Treatment of long-term calcified femoropopliteal artery lesions with directional arteriectomy and drug balloon | NCT02850107 |
|
Sabrina Wong Peixin Haroon 2016–2022 |
178 | Completed | Prevalence and progression of VC in maintenance hemodialysis patients in an Asian population and the efficacy of vit k2 supplementation in reducing the progression of VC in this group of patients | NCT02870829 |
|
Nadia Mohsen Abdu Ibrahim 2017–2021 |
40 | Completed | Clinical, laboratory, and VC outcomes in patients undergoing surgical parathyroidectomy within 6 months | NCT03724188 |
|
Thananda Trakarnvanich 2017–2019 |
201 | Completed | Effect of DPP4-inhibitors (gemigliptin) on biomarkers of kidney injury and vascular calcification in diabetic nephropathy | NCT04705506 |
|
Alshaimaa Sayed Hassan Mubarak 2018–2020 |
120 | Completed | Effects of intravenous injection of vit K1 on serum dephosphorylation-non-carboxylated MGP (dp-ucMGP) levels and aortic calcification scores and aortic and mitral valve disease severity | NCT05060809 |
|
Daniel Zickler 2018–2019 |
50 | Completed | The effect of MCO or highflux dialysis on VC | NCT03104166 |
|
Rehab Werida 2019–2020 |
60 | Completed | The effect of omega-3 fatty acids on the VC biomarkers Fetuin-A and OPG in dialysis patients | NCT03982966 |
|
Sarah Fahmy 2020–2021 |
40 | Completed | Effects of vit K2 (menadione, MK-7) supplementation with vit k1 on circulating levels of calcification regulators and to evaluate its safety in routine dialysis patients | NCT04477811 |
|
Takayuki Hamano 2014–2023 |
60 | Enrolling by invitation | To compare the effects of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification and vascular endothelial dysfunction | NCT02237534 |
|
Ekaterina Parshina 2019–2023 |
63 | Active, not recruiting | Changes of cardiovascular calcification in dialysis patients with end-stage renal disease after parathyroidectomy versus conservative control group | NCT03937349 |
|
- 2021–2023 |
20 | Active, not recruiting | To evaluate the safety and efficacy of shockwave coronary lithotripsy (IVL) system in the treatment of new, calcified, and narrowed coronary artery disease prior to stent placement | NCT05434676 |
|
Liu Jianghua 2021–2030 |
1400 | Recruiting | To observe the influence of statins on the occurrence and development of CAC in patients with T2DM and the dynamic changes of serum miR-32 in the progression of CAC in patients with T2DM, and the possibility of being used as a biomarker for the serological diagnosis or prognosis of CAC | NCT04889053 |
|
Charles O'Neill 2021–2023 |
62 | Recruiting | Whether citrate hemodialysis can reduce the course of VC | NCT04956120 |
|
Konstantinos Stavroulakis 2022–2024 |
50 | Recruiting | Evaluate the 12 months safety and efficacy of the combination of Shockwave Intravascular Lithotripsy and a polymer coated Drug Eluting Stent device, for PACSS 3 and PACSS 4 calcified femoropopliteal disease | NCT05291247 |
|
Flavio Ribichini 2023–2024 |
50 | Not yet recruiting | To investigate the treatment of calcified small coronary vessels with IVL plus drug balloon | NCT05625997 |